What is Aulos Bioscience?
Aulos Bioscience operates at the intersection of computational biology and clinical oncology. By leveraging the design capabilities of Biolojic Design and the strategic incubation of ATP, the company focuses on developing highly specific IL2-targeting antibodies. This methodology aims to overcome the limitations of traditional cancer treatments by creating functional antibodies that offer superior efficacy and safety profiles. As a player in the biotechnology sector, Aulos is currently navigating the complex transition from early-stage research to clinical-grade therapeutic development, targeting high-unmet-need solid tumor indications.
How much funding has Aulos Bioscience raised?
Aulos Bioscience has raised a total of $60M across 1 funding round:
Series A
$60M
Series A (2023): $60M with participation from ATP
Key Investors in Aulos Bioscience
ATP
A prominent life science venture capital firm that specializes in building and scaling innovative biotechnology companies from the ground up.
What's next for Aulos Bioscience?
With the recent infusion of capital, Aulos Bioscience is expected to prioritize the advancement of its lead candidates through rigorous clinical trials. The strategic roadmap likely involves scaling its computational design platform to identify additional therapeutic targets while simultaneously strengthening its intellectual property portfolio. As the company matures, the focus will shift toward establishing partnerships or internal capabilities for large-scale manufacturing and regulatory navigation. The current funding trajectory suggests a robust commitment to long-term value creation in the oncology space, with stakeholders closely monitoring the progression of its IL2-targeting assets as they move closer to potential commercialization milestones.
See full Aulos Bioscience company page
